ONO Pharmaceutical Co. Ltd. logo

ONO Pharmaceutical Co. Ltd. (JP3197600004)

Market Closed
3 Aug, 20:00
XSTU XSTU
12. 56
+0.04
+0.2794%
- Market Cap
9.33 P/E Ratio
0.15% Div Yield
0 Volume
1.79 Eps
12.53
Previous Close
Add Transaction
Day Range
12.34 12.73
Year Range
9.25 14.5
Want to track JP3197600004 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

JP3197600004 closed today higher at €12.56, an increase of 0.2794% from yesterday's close, completing a monthly increase of 1.0459% or €0.13. Over the past 12 months, JP3197600004 stock gained 10.1754%.
JP3197600004 pays dividends to its shareholders, with the most recent payment made on Dec 01, 2025. The next announced payment will be in In 1 month on Sep 29, 2026 for a total of €40.
The last earnings report, released on May 13, 2026, missed the consensus estimates by -8.18%. On average, the company has fell short of earnings expectations by -2.7267%, based on the last three reports.
ONO Pharmaceutical Co. Ltd. has completed 1 stock splits, with the recent split occurring on Mar 29, 2016.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on JPX (JPY).

JP3197600004 Chart

ONO Pharmaceutical Co. Ltd. (JP3197600004) FAQ

What is the stock price today?

The current price is €12.56.

On which exchange is it traded?

ONO Pharmaceutical Co. Ltd. is listed on XSTU.

What is its stock symbol?

The ticker symbol is JP3197600004.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.15%.

What is its market cap?

As of today, no market cap data is available.

Has ONO Pharmaceutical Co. Ltd. ever had a stock split?

ONO Pharmaceutical Co. Ltd. had 1 splits and the recent split was on Mar 29, 2016.

ONO Pharmaceutical Co. Ltd. Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. Gyo Sagara CEO
XSTU Exchange
JP3197600004 ISIN
Japan Country
4,287 Employees
29 Sep 2026 Last Dividend
29 Mar 2016 Last Split
- IPO Date

Overview

Ono Pharmaceutical Co., Ltd., is a global pharmaceutical company with a significant presence in the health care sector through its production, purchasing, and sales of pharmaceuticals and diagnostic reagents. With a broad portfolio that spans from cancer treatments to remedies for chronic conditions such as diabetes and heart failure, Ono Pharmaceutical stands out for its innovative approach to healthcare solutions. The company is actively involved in advanced research and collaboration efforts with renowned institutions and companies to discover and develop novel therapeutic drugs and treatments. Founded over 300 years ago in 1717, Ono Pharmaceutical has its headquarters in Osaka, Japan, showcasing a long-standing tradition in the pharmaceutical industry combined with cutting-edge research and development activities.

Products and Services

  • Opdivo Intravenous Infusion and Kyprolis Intravenous Injection - These products are designed for the treatment of malignant tumors, offering advanced options for cancer care.
  • Emend capsules/Proemend intravenous injections - Aimed at preventing chemotherapy-induced nausea and vomiting, enhancing patient comfort during cancer treatment.
  • Demser capsules - Used for alleviating symptoms in patients suffering from pheochromocytoma, a type of tumor affecting the adrenal glands.
  • Mektovi, Velexbru, and Braftovi capsules - These medications target malignant tumors, forming a crucial part of Ono Pharmaceutical's oncology portfolio.
  • ADLUMIZ tablets - Specifically developed for treating cancer cachexia, which involves weight loss and muscle depletion in cancer patients.
  • Glactiv tablets and Forxiga tablets - Offer treatments for type 2 diabetes, highlighting Ono Pharmaceutical's commitment to addressing this widespread chronic condition.
  • Onoact Intravenous Infusion - This medication is prescribed for tachyarrhythmia, an irregular heartbeat condition.
  • Opalmon tablets - Aimed at treating peripheral circulatory disorder, it helps in improving blood flow.
  • Coralan - Used for managing chronic heart failure, Coralan represents the company's interest in cardiology.
  • Orencia injections - These are designated for the treatment of rheumatoid arthritis, providing relief from the autoimmune disease's symptoms.
  • Rivastach patches - Developed for Alzheimer's disease, these patches address the cognitive decline associated with the condition.
  • Ongentys tablets - Aimed at patients with Parkinson's disease, these tablets focus on improving life quality by managing symptoms.
  • Parsabiv, Staybla tablets, Onon capsules and Dry Syrups - Catering to a range of conditions from dialysis support to treating overactive bladder, asthma, and allergic rhinitis.
  • JOYCLU intra-articular injection and Recalbon tablets - These offer treatments for joint function improvement and osteoporosis, respectively, further showcasing Ono Pharmaceutical's diverse healthcare solutions.

Contact Information

Address: 8-2, Kyutaromachi 1-chome
Phone: 81 6 6263 5670